Pembrolizumab Granted Approval for Hepatocellular Carcinoma

Patients with advanced hepatocellular carcinoma (HCC) who have progressed on sorafenib can now take FDA-approved pembrolizumab (Keytruda â , Merck & Co., Inc.). Approval was based on KEYNOTE 224 (NCT02702414), a single-arm, multicenter trial which enrolled 104 patients with HCC. For trial eligibility, patients were required to have disease progression on or after using sorafenib, measurable disease, and Child-Pugh Class A liver impairment. Patients were administered 200 mg of pembrolizumab a...
Continue reading

Soluble Fiber Added to Foods Is Linked to Liver Cancer

The health benefits of dietary soluble fiber are well established, but according to researchers at the University of Toledo, the source of that fiber makes all the difference: artificially enriching a diet with soluble fiber can cause liver cancer if insoluble fiber is not also consumed. Dietary soluble fiber promotes good health because it is fermented by gut bacteria into short-chain fatty acids. These acids reduce the symptoms of metabolic syndrome, a co-occurring constellation of condit...
Continue reading

Radiation Segmentectomy Shows Promise as Curative Therapy for Early HCC

Caption: Computed tomography scan of HCC before yttrium (left) and magnetic resonance image at 9-year follow-up (right).Credit: Radiological Society of North America. Results of a study published in Radiology support the use of radiation segmentectomy (RS) as a minimally invasive technique to treat early-stage hepatocellular carcinoma (HCC). Administered via catheter into the liver, RS uses the radioisotope yttrium-90 to attack tumor cells while leaving adjacent healthy tissue largely unharmed. ...
Continue reading

Hepatocellular Carcinoma: Current Challenges and Future Directions With Thomas A. Abrams, MD

Hepatocellular carcinoma (HCC) is the sixth most common tumor globally. Patients with HCC have a dismal prognosis, with a 5-year survival rate of 18%. Thomas A. Abrams, MD, assistant professor of medicine at Harvard Medical School, spoke with i3 Health about how strong physician-patient relationships and a multidisciplinary approach can facilitate the management of HCC and improve outcomes.  

Continue reading

Johns Hopkins Develops Noninvasive Blood Test for 8 Common Cancers

A high-throughput liquid handing robot processes samples for evaluation with the CancerSEEK test. Credit: Fred Dubs, Johns Hopkins Pathology Photography, Johns Hopkins University. Johns Hopkins Kimmel Cancer Center has developed a single, noninvasive blood test called CancerSEEK to screen for 8 types of common cancer. These include cancers of the ovary, liver, stomach, pancreas, esophagus, colorectum, lung, and breast, which account for more than 60% of cancer deaths in the US. Due to the noninv...
Continue reading
© Copyright 2018 i3 Health. All rights reserved.